Low-load blood flow restriction training to boost arm strength in people with COPD

Effects Of Low-Load Blood Flow Restriction Training Of The Upper Extremity In Patients With Chronic Obstructive Pulmonary Disease

Not applicable Interventional Inonu University · NCT07469111

This trial tests whether adding low-load blood flow restriction to arm exercises helps people with moderate COPD get stronger and improve upper-extremity function compared with a sham procedure.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment36 (estimated)
Ages40 Years to 80 Years
SexAll
SponsorInonu University Academic / other
Locations1 site (Malatya, Battalgazi)
Trial IDNCT07469111 on ClinicalTrials.gov

What this trial studies

People with COPD often cannot tolerate high-intensity exercise, which limits gains in peripheral muscle strength; low-load blood flow restriction training (LL-BFRT) may produce strength gains using much lower mechanical loads. This interventional study compares LL-BFRT plus aerobic exercise with a sham-BFRT plus the same aerobic program in clinically stable patients with GOLD stage 2–3 COPD. Eligible participants are adults 40–80 years old without recent exacerbations or contraindicating cardiovascular or vascular conditions and will perform supervised low-load upper-extremity resistance sessions alongside aerobic training. Primary outcomes focus on upper-extremity muscle strength, function, and tolerability of the intervention.

Who should consider this trial

Good fit: Ideal candidates are clinically stable adults aged 40–80 with GOLD stage 2–3 COPD, resting SpO2 ≥88%, MoCA ≥24, and no orthopedic, peripheral vascular, or recent cardiovascular contraindications to upper-extremity exercise.

Not a fit: Patients with uncontrolled hypertension, severe arrhythmia, recent myocardial infarction, deep vein thrombosis, peripheral vascular disease, active infection/open wounds, recent upper-extremity surgery, or significant cognitive impairment are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, LL-BFRT could allow people with COPD to gain meaningful arm strength and better perform daily activities while avoiding high-intensity loading that their lungs cannot tolerate.

How similar studies have performed: Low-load BFRT has produced strength gains in healthy and various clinical populations and small studies in COPD show promise, but evidence specifically for upper-limb BFRT in COPD remains limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Individuals aged 40-80 years with stage 2 and 3 COPD diagnosed according to GOLD criteria

  * Clinically stable COPD (no exacerbation in the last 6 weeks)
  * Stable medical treatment for at least 4 weeks
  * No orthopedic or neurological problems that would prevent them from performing upper extremity exercises
  * Resting SpO2 ≥ 88%
  * Able to understand and follow verbal instructions in Turkish
  * Individuals with a Montreal Cognitive Assessment Scale (MoCa) score ≥ 24 will be included.

Exclusion Criteria:

* Uncontrolled hypertension

  * Severe arrhythmia
  * Recent MI
  * Deep vein thrombosis
  * Peripheral vascular disease
  * Presence of infection or open wound
  * Having undergone upper extremity surgery within the last 6 months
  * Cognitive impairment or cooperation problems will be among the exclusion criteria

Where this trial is running

Malatya, Battalgazi

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Chronic Obstructive Pulmonary DiseaseBlood Flow Restriction TrainingLos Load Resistance ExerciseUpper Extremity FunctionMuscle Strength
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.